Korea’s Moon Care: Boon or Burden?
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Louis was the Senior Analyst and Editor-in-Chief from 2013 to 2019. He currently collaborates with PharmaBoardroom as external editor. Having directed pharmaceuticals & life science projects across 4 continents, he has published over 30 country reports as well as produced analytical studies on trends in blockchain, Pharma M&A and biotechnology. He has a professional background in consultan more...
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Takeda’s proposed acquisition of Shire may have come as a surprise to many commentators, but the appointment of an audacious French CEO in the form of Christophe Weber had already…
Ipsen CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From our…
A sudden imposition of import restrictions on pharmaceuticals in 2017 has pushed several multinational companies to establish local production facilities in Algeria. However, the localization process can be fraught both…
The global drop in oil prices in 2015-2016 hit the Algerian economy – which is heavily reliant on petroleum revenues – hard. The country’s government implemented severe economic cuts across…
Multinational pharmaceutical companies are increasingly choosing Algeria as a base for their regional headquarters, despite the complexities of the local market. The representatives of Lilly, bioMérieux and Abbott in Algeria…
Spanish stakeholders have been trailblazing the concept of the “liquid hospital”, which envisions the virtual and physical expansion of healthcare provision beyond the parameters of the traditional centralized hospital structure.…
Cyprus is capitalizing on its well-established tourism infrastructure to stake a claim for itself as one of Europe’s premier medical tourism destinations. “I believe Cyprus can become a really important…
The last few years have witnessed the advent of a highly disruptive business model within the heart of the pharma world that fundamentally reconsiders the manner in which R&D is…
Blue-chip drug makers holding USD 200 billion in cash, mostly overseas, will start investing more of it in mergers and acquisitions (M&A) after President Trump’s tax overhaul slashed the cost…
Digital health startups raised over USD six billion in equity financing in 2016, representing a five-year compound annual growth rate of 32 percent and the fledgling industry segment already boasts…
Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by…
See our Cookie Privacy Policy Here